Clinical trials: Solid Organ Transplant
Solid Organ Transplant
Seasonal Influenza Vaccine High Dose Boosting in Solid Organ Transplant Recipients
In solid organ transplant (SOT) the receipt of influenza vaccine in an influenza season is associated with decreased disease severity as demonstrated by the presence of pneumonia and ICU admissions.
- Trial name
- NCT05663463
- Testing
- Fluzone High-Dose - 2 doses, Fluzone High-Dose - 1 dose of HD
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- University of Minnesota
Solid Organ Transplant
iParent2Parent Program for Parents of Pediatric Solid Organ Transplant Recipients
The iParent2Parent (iP2P) program is a new, innovative virtual mentorship program that will connect parents one-to-one with other parents of pediatric solid organ transplant (SOT) recipients who are trained to offer vital peer…
- Trial name
- NCT05968807
- Testing
- iParent2Parent Program
- Where
- Canada
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- The Hospital for Sick Children
Monitoring, Immunologic, Active Tuberculosis
New Generation IGRA in Immunocompromised Individuals
Evaluation of a new ELISA based interferon-gamma release assay (QuantiFERON TB plus In-tube test) in immunocompromized patients
- Conditions
- Monitoring, Immunologic, Active Tuberculosis, Tuberculosis in Solid Organ Transplant Recipients, Tuberculosis in Marrow Transplant Recipients
- Trial name
- TBnet#54 (NCT02639936)
- Where
- 16 sites in Denmark, Germany and 8 more
- Volunteers
- 2,663 people, healthy volunteers welcome
- Sponsor
- Tuberculosis Network European Trialsgroup
Infection in Solid Organ Transplant Recipients
Pneumococcal Conjugate Vaccine 13 (Prevnar13®) in Children Who Are Solid Organ Transplant Recipients (SOT)
The purpose of this study is to determine the safety and long-term immunogenicity of the 13-Valent Pneumococcal Conjugate vaccine in children who are solid organ transplant recipients.
- Trial name
- NCT01527591
- Testing
- Pneumococcal Conjugate Vaccine 13 (PCV13)
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of California, Los Angeles
Solid Organ Transplant Recipient, Skin Cancer
The Organ Transplant Recipient HPV and Skin Cancer Study
Solid organ transplant recipients (OTRs) receive lifelong immunosuppressive therapy, which puts them at increased risk of cutaneous and mucosal cancers.
- Conditions
- Solid Organ Transplant Recipient, Skin Cancer, Skin Dysplasia, HPV Infection
- Trial name
- NCT05284877
- Testing
- No intervention
- Where
- 3 sites in Denmark
- Volunteers
- 1,500 people
- Sponsor
- Merete Haedersdal
Solid Organ Transplant Complications
Microbiota Transplantation in Solid Organ Transplantation
Solid organ transplantation (SOT), an alternative therapy for end-stage diseases, offers increased longevity and better quantity of life.
- Trial name
- NCT06730451
- Testing
- Washed Microbiota Transplantation
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The Second Hospital of Nanjing Medical University
Solid Organ Transplant Recipients, Autoimmune Diseases
Mass Evaluation of Lateral Flow Immunoassays for the Detection of SARS-CoV-2 (Covid-19) Antibodies
DESIGN Observational epidemiological study AIMS - To determine: 1. The proportion of immunosuppressed people who have detectable SARS-CoV-2 antibodies following a primary vaccine course (3 doses), and the demographic, disease…
- Conditions
- Solid Organ Transplant Recipients, Autoimmune Diseases, Haematological Malignancies
- Trial name
- MELODY (NCT05148806)
- Testing
- self-administered lateral flow assays
- Where
- 4 sites in United Kingdom
- Volunteers
- 28,411 people
- Sponsor
- Imperial College London
Solid Organ Transplant Complications
Washed Microbiota Transplantation in Solid Organ Transplantation
Solid organ transplantation (SOT), an alternative therapy for end-stage diseases, offers increased longevity and better quantity of life.
- Trial name
- NCT06708676
- Testing
- Washed Microbiota Transplantation
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The Second Hospital of Nanjing Medical University
Solid Organ Transplant Rejection, Organ Rejection Transplants
Expanded Access for Use of ExoFlo in Abdominal Solid Organ Transplant Patients
This Expanded Access Protocol will provide access to the IMP ExoFlo for patients who have severe or life-threatening abdominal solid organ transplant rejection or who are evaluated and determined to be at high risk of progression…
- Conditions
- Solid Organ Transplant Rejection, Organ Rejection Transplants, Organ Rejection
- Trial name
- NCT05215288
- Testing
- ExoFlo
- Where
- 2 sites in United States
- Sponsor
- Direct Biologics, LLC
Cytomegalovirus Infections, Solid Organ Transplant
A Dose-Escalation Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against CMV in Adult Solid Organ Transplant Recipients
This study measures the tolerability of viral-specific T cells against Cytomegalovirus (CMV) in adult solid organ transplant (SOT) recipients. Participants are expected to be on study for 52 +/- 3 weeks.
- Trial name
- NCT03950414
- Testing
- CMV specific T-cells
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Wisconsin, Madison
Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease
Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease
While hematopoietic stem cell transplant (HSCT) is an effective therapy, graft versus host disease (GVHD) is the most significant complication after HSCT.
- Conditions
- Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease, Solid Organ Transplant
- Trial name
- NCT05121142
- Testing
- Ruxolitinib
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Solid Organ Transplant
iPeer2Peer Pediatric Thoracic Transplantation
With the on-going presence of a chronic illness, daily immunosuppressive medications, and the need for continuous medical supervision, pediatric transplant recipients face considerable psychosocial stresses.
- Trial name
- NCT04253548
- Testing
- iPeer2Peer Support Mentorship Program
- Where
- Canada
- Volunteers
- 34 people
- Sponsor
- The Hospital for Sick Children
Pediatric Solid Organ Transplant
Continuous Hemoglobin Monitoring in Pediatric Transplant
The purpose of this study is to determine the clinical utility of non-invasive monitoring of Hemoglobin (Hgb) and Plethysmograph Variability Index (PVI) values during the intraoperative period of visceral solid organ…
- Trial name
- NCT00958984
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Nebraska
Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders
Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies
The primary objective of this protocol is to provide expanded access to tabelecleucel to participants with Epstein-Barr virus-associated diseases and malignancies for whom there are no other appropriate therapeutic options, and…
- Conditions
- Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders, EBV+ Associated Lymphoma, EBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)
- Trial name
- NCT02822495
- Testing
- tabelecleucel
- Sponsor
- Atara Biotherapeutics
Autoimmune or Autoinflammatory Diseases, HIV
Study of the Humoral Response to SARS-CoV-2 Variants and of the Cellular Response After Vaccination Against COVID-19 in Immunocompromised People
Prospective, multicenter, non-comparative cohort study of immunocompromised people vaccinated against Covid-19 with the aim to know the humoral and cellular response to BNT162b2 vaccination against SARS-CoV-2 variants.
- Conditions
- Autoimmune or Autoinflammatory Diseases, HIV, Multiple Sclerosis, Solid Tumors or Cancers
- Trial name
- COVIVAC-ID (NCT04844489)
- Testing
- Blood samples for the study of the humoral response to SARS-CoV-2 variants and of the cellular response after vaccination against COVID-19
- Where
- France
- Volunteers
- 377 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Solid Organ Transplant, Heart Transplant
REmote moBile Outpatient mOnitoring in Transplant 2.0
This study is designed to determine if an innovative mobile health intervention designed to improve patient-provider communication can reduce unscheduled hospitalizations, and visits to the emergency department and ambulatory…
- Conditions
- Solid Organ Transplant, Heart Transplant, Liver Transplant, Kidney Transplant
- Trial name
- Reboot (NCT04721288)
- Testing
- Active communication through Reboot application, Generic communication through Reboot application
- Volunteers
- 400 people
- Sponsor
- University Health Network, Toronto
Solid Organ Transplant Recipients
TIXAGEVIMAB/CILGAVIMAB Protection of Covid-19 in Transplanted Patients
Covid-19 has a very bad prognosis in solid organ transplant recipients with a 60 days-mortality exceeding 20%. For this reason, transplant patients were prioritized to receive Covid-19 vaccination since December 2020 in France.
- Trial name
- TIXCI-TRANS (NCT05234398)
- Testing
- Blood and saliva samplings
- Where
- 2 sites in France
- Sponsor
- Hospices Civils de Lyon
Infection in Solid Organ Transplant Recipients
The Incidence and Risk Factors for Clostridioides Difficle Infection in Solid Organ Transplant Recipients
2.1. Study Objectives Primary Objective(s) Identify the incidence and risk of CDI within one year after kidney, liver, and/or pancreas transplant Secondary Objective(s) Identify the risk factors for recurrent CDI post-transplant…
- Trial name
- NCT04637321
- Testing
- Solid organ transplant
- Where
- United States
- Volunteers
- 585 people
- Sponsor
- Methodist Health System
COVID-19, SARS-CoV-2 Infection
Immune Response to Third Dose of COVID-19 Vaccine in Solid Organ Transplant
The Coronavirus Disease 2019 (COVID-19) pandemic has claimed over 5 million lives globally. Fortunately, a substantial and growing number of SARS-CoV-2 vaccines with very high efficacy have been developed, manufactured, and…
- Conditions
- COVID-19, SARS-CoV-2 Infection, Solid Organ Transplant, Vaccine Response Impaired
- Trial name
- NCT05124509
- Testing
- Three doses of SARS-CoV-2 BNT162b2 vaccine (observational), Two doses of CoronaVac and one dose of BNT162b2 SARS-CoV-2 vaccine (observational)
- Where
- Chile
- Volunteers
- 147 people
- Sponsor
- Pontificia Universidad Catolica de Chile
Invasive Fungal Infection, Hematological Malignancy
Prospective Clinical Evaluation of Beta-D-Glucan Assay in Blood and BAL
In patients with invasive fungal infection (IFI) rapid diagnosis is essential for early initiation of appropriate antifungal therapy and thereby survival. Conventional culture is still the Gold-Standard for diagnosis of IFI.
- Conditions
- Invasive Fungal Infection, Hematological Malignancy, Receipt of Solid Organ Transplant
- Trial name
- NCT01576653
- Testing
- Fungitell Assay in BAL
- Where
- Austria
- Volunteers
- 100 people
- Sponsor
- Robert Krause, MD